

Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765, Imbruvica) is an FDA approved drug that targets B-cell malignancies and is approved for treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and waldenstrom macroglobulinemia. Orally-bioavailable compound that is a potent and selective inhibitor of bruton's tyrosine kinase (BTK).

Materials Provided

Catalog Number:	92-1243
Quantity Supplied:	1 vial(s), 5 mg per vial

Description

DiscoverX control ligands have been functionally tested and validated for optimal use with all cell line targets and Assay Ready kits.

Product Information

Molecular Weight:	440.5 g/mol
Source:	Synthetic
Purity:	≥ 99%
Endotoxin Level:	N/A
Formulation:	N/A
Storage:	-20°C Please avoid multiple freeze/thaw cycles.

Reagent Preparation

To avoid condensation, equilibrate the vial to ambient temperature before opening.

Stock Concentration:	10 mM
Reconstitution Volume:	1.135 mL
Reconstitution Solvent:	DMSO

For Research Use Only

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com
Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com
General product information: www.discoverx.com